<DOC>
	<DOCNO>NCT00168883</DOCNO>
	<brief_summary>This randomize study ass efficacy safety chemotherapy platin compare chemotherapy without platin .</brief_summary>
	<brief_title>Study Patients With Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Randomized Phase II design , multicenter study , assess efficacy safety combine chemotherapy Paclitaxel Carboplatin versus platinum free chemotherapy Paclitaxel Vinorelbine , within combination therapy two different dose interval , assess well ( 4 Arm study ) .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Chemotherapy naive patient histologically confirm NSCLC stage III IV New York Heart Association ( NYHA ) III IV Brain metastases Neurotoxicity Grade 2 great</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>curative non-treatable NSCLC UICC stage IIIB IV</keyword>
</DOC>